Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab

Scandinavian Journal of Rheumatology

Volumn 40, Issue 2, 2011, Pages 150-160

  Tarkiainen, M ^a   Tynjala ^b   Vahasalo P ^a   Lahdenne, P ^a  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CALGRANULIN; ETANERCEPT; INFLIXIMAB; LACTOFERRIN; SALAZOSULFAPYRIDINE;

ADOLESCENT; CLINICAL PRACTICE; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SPONDYLOARTHROPATHY; TREATMENT RESPONSE;

EID: 79952369460     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2010.499878     Document Type: Letter

References (9)

1. Prince FH, Twilt M, ten Cate R, van Roussum M, Armbrust W, Hoppenreijs E, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
2. Horneff G, De Bock F, Foeldvari I, Girschick H, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis 2009;68:519-25.
3. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106. (Pubitemid 47502757)
4. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52.
5. Akobeng AK. Crohn's disease: current treatment options. Arch Dis Child 2008;93:787-92.
6. Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology 2009;48:761-4.
7. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
8. Turunen P, Ashorn M, Auvinen A, Iltanen S, Huhtala H, Kolho K-L. Long-term health outcomes in pediatric inflammatory bowel disease: a population-based study. Inflamm Bowel Dis 2009;15:56-62.
9. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(Suppl 4):36-42. (Pubitemid 39319245)